✦ LIBER ✦

8 24 Week treatment regimen with peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in HCV genotype 1 or 4 ‘super-responders’

✍ Scribed by P. Ferenci; U. Bergholz; H. Laferl; T.M. Scherzer; A. Maieron; M. Gschwantler; H. Brunner; R.R. Hubmann; C. Datz; M. Bischof; R. Stauber; P. Steindl-Munda

Book ID: 117374291
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 159 KB
Volume: 44
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(06)80009-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

O.161 High SVR rates with 24 weeks of pe

O.161 High SVR rates with 24 weeks of peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in HCV genotype 1 or 4 patients with a week-4 virological response

✍ P. Ferenci; T. Scherzer; H. Laferl; K. Staufer; A. Maieron; M. Gschwantler; H. B 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 140 KB

734 Peginterferon alpha-2a (PEGASYS) plu

734 Peginterferon alpha-2a (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks in patients with HCV genotype 2 OR 3. Final results of the accelerate trial

✍ M.L. Shiffman; S. Pappas; L. Nyberg; S. Greenbloom; A. Gibas; B. Bacons; J. Rase 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 124 KB

609 Predicting response and anaemia in H

609 Predicting response and anaemia in HCV genotype 1 patients treated with peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®): A generalised additive logistic model (GAM) analysis

✍ E. Snoeck; J.R. Wade; M. Lamb; E. Duff; K. Jorga 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 127 KB

566 Pharmacokinetics and pharmacodynamic

566 Pharmacokinetics and pharmacodynamics of induction doses of peginterferon alpha-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®) in HCV genotype 1 patients who failed to respond to interferon/ribavirin

✍ M. Diago; M. Romero-Gomez; J. Crespo; A. Olveira; R. Perez; R. Barcena; J.M. San 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 265 KB

O.160 16 or 24 weeks of peginterferon al

O.160 16 or 24 weeks of peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) in patients with HCV genotype 2 or 3 and bridging fibrosis or cirrhosis: Results from a large, randomised multinational study (ACCELERATE)

✍ S. Zeuzem; S. Pappas; L. Nyberg; S. Greenbloom; A. Gibas; B. Bacon; E. Godofsky; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 143 KB

P.411 The impact of age on sustained vir

P.411 The impact of age on sustained virological response in genotype 1 HIV-HCV co-infected patients receiving peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®): AIDS PEGASYS ribavirin co-infection trial (APRICOT)

✍ J. Rockstroh; F.J. Torriani; M. Rodriguez Torres; E. Lissen; A. Lazzarin; J. De 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 274 KB